1 Estimated pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the 2 **COVID-19** pandemic Karl W. Boehme, PhD^{1,2,3#}, Joshua L. Kennedy, MD^{4,5,6,#}, Jessica Snowden, MD⁴, Shana M. 3 Owens, PhD¹, Marianne Kouassi, BS¹, Ryan L. Mann, BS¹, Amairani Paredes, BS¹, Claire Putt, BA⁴, Laura James, MD⁴, Jing Jin, MPH⁷, Ruofei Du, PhD⁷, Catherine Kirkpatrick, BS⁶, Zeel 4 5 Modi, BA⁵, Katherine Caid, BS⁵, Namvar Zohoori, MD, MPH, PhD^{7, 8}, Atul Kothari, MD^{5, 8, 9}, 6 Bobby L. Boyanton, Jr., MD¹⁰, and J. Craig Forrest, PhD^{1,2,3} 7 8 9 ¹ Department of Microbiology & Immunology, College of Medicine, University of Arkansas for 10 Medical Sciences, Little Rock, AR 11 ²Center for Microbial Pathogenesis and Host Inflammatory Responses, University of Arkansas 12 for Medical Sciences, Little Rock, AR ³ Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little 13 14 Rock, AR ⁴ Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, 15 16 Little Rock, AR ⁵ Department of Internal Medicine, College of Medicine, University of Arkansas for Medical 17 18 Sciences, Little Rock, AR ⁶ Arkansas Children's Research Institute, Little Rock, AR. 19 20 ⁷ Department of Biostatistics, College of Public Health, University of Arkansas for Medical 21 Sciences, Little Rock, AR ⁸ Arkansas Department of Health, Little Rock, AR. 22 ⁹ Department of Bioinformatics, College of Medicine, University of Arkansas for Medical 23 24 Sciences, Little Rock, AR ¹⁰ Departments of Pathology, Arkansas Children's Hospital and University of Arkansas for 25 26 Medical Sciences, Little Rock, AR 27 28 [#]These authors contributed equally to the work. 29 [‡]Correspondence to: 30 31 Karl W. Boehme 32 Mailing address: 4301 W. Markham Dr. #511, Little Rock, AR 72205 Phone: (501) 686-5189 33 34 Email: kwboehme@uams.edu 35 36 J. Craig Forrest 37 Mailing address: 4301 W. Markham Dr. #511, Little Rock, AR 72205 Phone: (501) 38 39 Email: jcforrest@uams.edu 40 41 Joshua L. Kennedy Mailing address: 13 Children's Way, Slot 512-13, Little Rock, AR 72205 42 43 Phone: (501) 364-1060 44 Email: jlkennedy@uams.edu 45 46 Running Title: Pediatric SARS-CoV-2 seroprevalence in Arkansas 47 Keywords: COVID-19, SARS-CoV2, serology, antibody, child, epidemiology

48 ABSTRACT

49	Importance:	As vaccines	for children	under the age of	12 are not ye	t approved,	determining the
				0			0

- 50 SARS-CoV-2 infection rate in children is important for decisions about protective measures to
- 51 be taken during the 2021–2022 school year.
- 52
- 53 **Objective:** To estimate the prevalence of SARS-CoV-2 antibodies in residual serum samples
- 54 from pediatric patients in the state of Arkansas over the first year of the COVID-19 pandemic as
- an indicator of SARS-CoV-2 infection rates in children.
- 56
- 57 **Design:** The study is a survey of SARS-CoV-2 seropositivity in children in Arkansas over the

58 first year of the COVID-19 pandemic. Fom April 2020 through April 2021, remnant serum

samples were collected across five time periods (waves): April 2–May 6, June 6–August 10,

60 September 8–October 17, November 7–December 17, 2020 and April 5–April 28, 2021.

61

Setting: The multi-site survey collected remnant serum samples from four clinics across the
state of Arkansas: Arkansas Children's Hospital (ACH, Little Rock, AR), Arkansas Children's
Northwest (Springdale, AR), and UAMS Family Medical Centers (Ft. Smith, AR and Pine Bluff,
AR)

66

67 Participants: The study population consisted of 2400 convenience serum samples from
68 children ages 1–18 who visited hospitals or regional clinics in Arkansas for non-COVID1969 related reasons.

70

71 **Exposures:** Infection with SARS-CoV-2.

72

73 Main outcomes and measures: The presence of IgM and/or IgG antibodies to the SARS-CoV-74 2 Spike and Nucleoprotein were determined using a two-step enzyme-linked immunosorbent 75 assay. Seroprevalence was estimated by demographic group, including age (1-4, 5-9, 10-14, 76 and 15-18 years), sex, race/ethnicity (white, black, Hispanic), metropolitan status, SARS-CoV-2 77 PCR testing, and co-morbidities (respiratory virus infection within 6 months, asthma, 78 hypertension, obesity, diabetes, autoimmune disease). Association with SARS-CoV-2 antibody 79 reactivity was determined by demographic group. 80 81 Results: The overall SARS-CoV-2 seroprevalence rose from 7.9% in Wave 1 (95%CI, 4.9-82 10.9%) to 25.8% in Wave 5 (95% CI, 22.2-29.3%), as did the age- and sex-standardized 83 seroprevalence rate which ranged from 8.6% in Wave 1 (95%CI, 5.1-11.1%) to 24.2% in Wave

5 (95% CI, 20.1-28.2%). Hispanic children had a significantly higher risk of testing positive for

85 SARS-CoV-2 antibodies than non-Hispanic white children in Wave 3 (RR 2.82, 95% CI, 1.81-

4.38), Wave 4 (RR 1.76, 95% CI, 1.03-3.00), and Wave 5 (RR 2.37, 95% CI, 1.69-3.33)

87 Similarly, black children also showed a significantly higher risk of testing positive for SARS-CoV-

2 antibodies than white children in Wave 3 (RR 1.71, 95% CI, 1.03-2.84) and Wave 5 (RR 1.59,

89 95% CI, 1.08-2.34).

90

91 Conclusions and relevance: The percentage of Arkansas children with SARS-CoV-2-specific 92 antibodies increased from April 2020 to April 2021. These data indicate that many more children 93 have been infected with SARS-CoV-2 than indicated by diagnostic testing. With the emergence 94 of SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or 95 asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these 96 results highlight the importance of including children in SARS-CoV-2 public health, clinical care, 97 and research strategies. These findings are important for state and local officials as they

- 98 consider measures to limit SARS-CoV-2 spread in schools and daycares for the 2021–2022
- 99 school year.

100 INTRODUCTION

101 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 and spread globally to cause the coronavirus disease of 2019 (COVID-19) pandemic.^{1,2} SARS-102 103 CoV-2 has infected nearly 200 million and killed more than 4 million people worldwide, causing massive disruptions to daily life and untold economic losses.³ SARS-CoV-2 was first detected in 104 the United States in early 2020 and has caused over 600,000 deaths.⁴⁻⁶ Children were thought 105 to be important for driving SARS-CoV-2 transmission.^{7,8} In March 2020, schools nationwide 106 107 closed for in-person instruction and classes moved online to curtail SARS-CoV-2 spread.^{7,8} 108 However, pediatric infection rates, and thereby the potential level of immunity in children, is not known.^{9,10} Because approval of SARS-CoV-2 vaccines for those 12 years and under is not 109 110 expected until late 2021, knowing infection rates in children is important information for school 111 officials as they consider risks and protection measures for the 2021–2022 school year. 112 Children typically experience less severe COVID-19 and may be more likely to have asymptomatic infections, allowing them to unknowingly spread SARS-CoV-2.¹¹ With 113 114 asymptomatic infections estimated as high as 50%, estimating true infection rates remains challenging.^{12,13} Although nucleic acid testing can identify active SARS-CoV-2 cases, most 115 infections clear within two weeks and leave asymptomatic cases undocumented.¹²⁻¹⁴ Antibodies 116 generated against prior infections can last for months to years.^{10,15} The presence of SARS-CoV-117 118 2 antibodies in the blood can indicate that a person was infected at some point in the pandemic. 119 Serological studies can capture asymptomatic and symptomatic cases, and more accurately estimate of how many people have been infected with SARS-CoV-2.^{10,15} Here, we present the 120 121 results of a seroprevalence study of children ages 1-18 years of age who visited hospitals or 122 regional clinics for non-COVID19-related reasons in the state of Arkansas over the first year of 123 the COVID-19 pandemic.

124

125

126 METHODS

127 Human specimens. All human specimens were obtained with oversight from the UAMS 128 Institutional Review Board (IRB), and waiver of consent and HIPAA applied. Remnants of serum 129 samples collected for routine, non-COVID-19-related clinical laboratory tests were obtained from 130 Arkansas Children's Hospital (ACH, Little Rock, AR), Arkansas Children's Northwest 131 (Springdale, AR), and UAMS Family Medical Centers (Ft. Smith, AR and Pine Bluff, AR). 132 Samples were de-identified prior to testing. Inclusion criteria were ages 1-18 years and 133 Arkansas resident. Samples were excluded with the following diagnosis codes: 134 immunodeficiency (primary immune deficiency (D80–D89)), transplant recipient (codes 135 beginning with Z94), and cancer (C00–D49). Samples from patients receiving chemotherapy 136 (prior two months), steroids (prior 30 days), and/or intravenous immunoglobulin (prior 6 months) 137 were excluded. Samples were selected by pathologists at each clinic after they were considered remnant. Clinical and demographic variables were stored in a secure REDCap database^{16,17} 138 139 and included age, sex, race, ethnicity, zip code, and county of residence. Metropolitan status 140 was determined by cross-referencing zip codes with the Federal Office of Rural Health Policy 141 (FORHP) data files identifying non-metropolitan counties and rural census tracts. 142 **Protein production and purification.** HEK 293T cells were cultured in Dulbecco's 143 minimum essential media (DMEM; Gibco) supplemented with 10% heat-inactivated calf serum 144 (CS, VWR), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin/100 µg/mL streptomycin (Invitrogen). Briefly, 15 cm dishes seeded with 9×10^6 cells on the preceding day were 145 146 transfected with 20 µg of pCAGGS-SARS-CoV-2 Wuhan-Hu-1 RBD with C-terminal 6-His tag 147 (BEI Resources), pCAGGS SARS-CoV-2 Wuhan-Hu-1 ectodomain Spike glycoprotein gene 148 with C-terminal 6-His tag, or pCMV3 2019-nCoV nucleoprotein with C-terminal 6-His tag (Sino 149 Biological) using polyethylamine (PEI) at a 1:3 ratio. DNA:PEI mixtures were incubated at RT for 150 10 mins and added to cells with the media volume reduced to 5 mL/dish. After 4–6 hours, the 151 media volume was raised to 25 mL. SARS-CoV-2 RBD and Spike ectodomain proteins were

purified as described.¹⁸ Nucleoprotein (N) was isolated as described above under denaturing
 conditions.¹⁹ Protein concentration was measured by DC Protein Assay (BioRad). Purified
 proteins were confirmed by Coomassie and western blot using antigen-specific antibodies and
 stored at -80°C.

ELISAs. Serum was inactivated at 56°C for 1 h and initially screened by ELISA specific 156 for the receptor-binding domain (RBD) of the SARS-CoV-2 S protein.²⁰⁻²⁶ Commercial anti-RBD 157 158 (Sino Biologicals; 1:2500 dilution) and SARS-CoV-2-RT-PCR-positive patient sera (1:50 159 dilution) served as positive controls. Purified human IgG (Sigma; 1:2500 dilution) and pre-160 COVID-19 patient sera (1:50 dilution) served as negative controls. Serum IgM and IgG were 161 detected using horse-radish peroxidase-conjugated anti-human IgM+IgG (Jackson 162 ImmunoResearch; diluted 1:5000 in PBS-T + 1% milk) and SureBlue TMB 1-Component 163 Peroxidase Substrate (SeraCare; 75 µL). After 5 min, the reaction was terminated using TMB 164 Stop Solution (SeraCare: 75 μ L). The OD₄₅₀ was measured using a FluoStar Omega plate 165 reader (BMG Labtech). The final OD_{450} was calculated by subtracting the mean OD_{450} of blank 166 wells from the mean OD₄₅₀ of duplicate samples. The statistical cutoff for RBD binding was defined as the mean OD₄₅₀ + 3 standard deviations of pre-COVID-19 sera.²⁶ 167 168 Confirmation RBD-positive specimens was performed using a Four-Antigen Confirmation 169 Test (FACT) ELISA. An additional 5% of negative sera were randomly selected and tested in 170 parallel. Plates were coated with 2 µg/mL RBD, spike, nucleoprotein, or bovine serum albumin 171 (BSA; Sigma Aldrich) and FACT ELISA was performed as above. Confirmed positive samples 172 were defined by (i) a mean signal for any viral antigen over 0.6 OD₄₅₀, (ii) BSA-subtracted viral 173 antigen value >0.3 OD_{450} , (iii) and at least two positive antigens (RBD+/Spike+, RBD+/N+, 174 Spike+/N+, or RBD+/Spike+/N+). The sensitivity and specificity of the assay were 94.6% and 175 100%, respectively, based on 37 pre-COVID-19 and 19 RT-PCR-confirmed SARS-CoV-2-176 positive sera.

177 Statistical analyses. The descriptive analysis was conducted for the study population 178 demographics by wave. SARS-CoV-2 antibody positivity rates were reported with 95% 179 confidence intervals (CI) using exact binomial distributions. The 2019 U.S. Census Bureau 180 Arkansas state population estimates (age≤18) were used to calculate the standardized positivity rates.²⁷ The age- and sex-standardized positivity rates were reported for each wave. Univariable 181 182 and multivariable analyses were performed to examine the relationship between variables and 183 the SARS-CoV-2 antibody positivity rate for each wave. Relative risk was estimated by modified 184 Poisson regressions with robust error variance as the measure to characterize association effects.²⁸ For multivariable analyses, factors being considered were age group, sex, and 185 186 race/ethnicity. The statistical significance level was set at 0.05. We conducted all analyses using 187 SAS version 9.4 (SAS Institute).

188

189 **RESULTS**

190 Enrollment and demographic representation. We collected 2400 total remnant 191 pediatric serum samples across five collection periods: Wave 1, April 2–May 6, 2020 (n=316); 192 Wave 2, June 6-August 10, 2020, (n=300); Wave 3, September 8-October 17, 2020, (n=594); 193 Wave 4, November 7–December 17, 2020, (n=600); and Wave 5, April 5–April 28, 2021, 194 (n=590) (Figure 1). Table 1 shows the demographic characteristics for the study. The 1–4 years 195 age group had the fewest samples (n=328, 13.7%) while the 10-14 years group had the most 196 samples (n=795, 33.2%). Females represented 54.8% (n=1311), whereas males represented 197 45.2% (n=1082) of total samples analyzed. The racial/ethnic distribution of the study population 198 was 55.8% non-Hispanic white (n=1289), 22.5% non-Hispanic black (n=520), and 15.2% 199 Hispanic (n=351). A total of 151 specimens (6.5%) were collected from patients that did not 200 identify as white, black, or Hispanic. Most samples were collected from children living in urban 201 (n=1564, 75.3%) compared to rural areas (n=513, 24.7%). Obesity was the most common co-

202	morbidity reported (n=337, 14.1%), followed by asthma (n=239, 10.0%), diabetes mellitus
203	(n=113, 4.7%), and hypertension (n=111, 4.6%) (Supplemental table 1).

204 **Estimates of seroprevalence.** Table 2 shows the SARS-CoV-2 seroprevalence rates 205 by age, sex, and race/ethnicity, and the age- and sex-standardized estimates. The antibody 206 positivity rate for Wave 1 was 7.9% (95% CI, 4.9%-10.9%), which increased in Wave 2 to 9.7% 207 (95% CI, 6.3%-13.0%) and Wave 3 to 16.2% (95% CI, 13.2%-19.1%), followed by a slight 208 decrease to 13.2% (95% CI, 10.5%-15.9%) in Wave 4. The seroprevalence rate was the highest 209 in Wave 5 at 25.8% (95% CI, 22.2%-29.3%). The overall trend was statistically significant 210 (p<0.0001 using the Cochran-Armitage trend test). When standardized to match Arkansas population demographics,²⁷ seroprevalence rates followed a similar trend to the non-adjusted 211 212 rates, increasing over Waves 1, 2, and 3, with a decrease in Wave 4 and a peak of 24.2% (95% 213 CI, 22.2%-29.3%) in Wave 5. The 1–4 year-old age group had the highest seroprevalence rates 214 in Wave 1 (10.7%), Wave 2 (15.2%), and Wave 3 (19.8%), but the lowest in Wave 4 (7.2%) and 215 Wave 5 (16.0%). The 15-18 year-old group had the highest percentage of reactive specimens in 216 Wave 4 (14.8%) and 10-14 year-olds were the highest in Wave 5 (30.9%). No statistically-217 significant difference was observed between males and females. 218 Hispanics had the highest seroprevalence rate in each wave, reaching a maximum of 219 43.7% in Wave 5. White persons had a higher seroprevalence rate in Waves 1 and 2, but the 220 lowest in Waves 3, 4, and 5. Concomitantly, the antibody reactivity rate in black persons was 221 lower compared to white persons in Waves 1 and 2, but higher in Waves 3, 4, and 5. The 222 highest seroprevalence rates for white (17.9%) and black (28.2%) children was observed in 223 Wave 5. Notably, the peak seroprevalence for Hispanic children was 5.5-fold higher compared 224 to white children and 1.6-fold higher than black children.

There was no significant marginal association between age, sex, or metropolitan status and the likelihood of testing positive for SARS-CoV-2 antibodies (Supplemental table 2). However, Hispanic and black children were more likely to test positive for antibodies than white

228 children during multiple waves after adjusting for age and sex. Hispanic children showed a 229 higher relative risk of testing positive compared to white chldren in Wave 3 (RR 2.82 95% CI, 230 1.81-4.38), Wave 4 (RR 1.76 95% CI, 1.03-3.00), and Wave 5 (RR 2.37 95% CI 1.69-3.33). 231 Blacks also showed a higher risk of having antibodies compared to white children in Wave 3 232 (RR 1.71 95% CI, 1.03-2.84) and Wave 5 (RR 1.59 95% CI, 1.08-2.34). The risk of testing 233 positive for antibodies was higher for children of other races/ethnicities in Wave 3 (RR 2.59 95% 234 CI, 1.36-4.92) and Wave 5 (RR 2.14 95% CI, 1.35-3.40). 235 Children with asthma (unadjusted RR 4.83 95% CI. 1.96-11.87; P=0.003) or diabetes 236 (unadjusted RR 4.17 95% CI, 1.49-11.67; P=0.007) had higher risk of having antibodies of 237 SARS-CoV-2 than children who did not have asthma or diabetes in Wave 1 (Supplemental table 238 3). However, this difference was not observed in the remaining waves. PCR testing was 239 performed for 714 of 2400 total specimens, with 38 positive PCR tests reported (Supplemental 240 table 4). A positive RT-PCR test was significantly associated with antibody positivity in Waves 2 241 through 5 (Supplemental table 5).

242

243 **DISCUSSION**

244 Our results demonstrate that by the end of April 2021, approximately 25% of children in 245 Arkansas had SARS-CoV-2-specific antibodies. This percentage is much higher than the total 246 number of confirmed cases, which on April 28, 2021 was 11% for the total population of 247 Arkansas (335,288 positive cases according the Arkansas Department of Health, population of 248 3.011.524 according to 2019 census data). This finding indicates that those children had been 249 infected with SARS-CoV-2 and are likely to have at least some natural immunity. Conversely, 250 our findings suggest that most children in Arkansas have not been infected with SARS-CoV-2 251 and remain susceptible to infection. Although COVID-19 has been less severe in children than 252 adults early in the pandemic, emergence of the SARS-CoV-2 delta variant in May 2021 has driven up infection and hospitalization rates, including among those under 18 years of age.^{11,29,30} 253

Developing multisystem inflammatory syndrome in children (MIS-C), a severe inflammatory
disorder that results from a current or recent SARS-CoV-2 infection, is also a risk for those
under 18 years.³¹⁻³³ Increased SARS-CoV-2 transmission rates combined with a highly
susceptible pediatric population raises the possibility that SARS-CoV-2 could spread rapidly in
schools and daycares during the upcoming school year. More children infected with SARS-CoV-2
2 could lead to an increase in the number of severe COVID-19 and MIS-C cases, and a rise in
pediatric deaths.

The first SARS-CoV-2 infections in Arkansas were reported in March 2020 (Figure 1).³⁴ 261 262 Arkansas schools suspended in-person learning on March 15, 2020 and many activities where 263 children congregate during the summer were closed. We found that the seroprevalence rate in 264 children increased modestly between spring and summer, suggesting that these protective 265 measures effectively limited SARS-CoV-2 spread among children in Arkansas. The larger 266 increase in seroprevalence for September/October (Wave 3), corresponded with the start of the 267 2020-2021 school year. However, masks and social distancing measures were in place, and 268 many Arkansas students began the school year as remote learners. These actions likely 269 reduced SARS-CoV-2 spread in schools, as reported outbreaks were relatively rare. Despite a dramatic increase in SARS-CoV-2 cases in Arkansas during November and December, the 270 seroprevalence rate in children dropped during Wave 4.³⁵ The decrease suggests that 271 272 preventative measures in schools were effective at limiting SARS-CoV-2 spread among children 273 during this time. However, seroprevalence increased sharply in Wave 5 to approximately 25%. 274 Waves 4 and 5 were approximately three months apart and included the winter holidays, when 275 children were outside the controlled school setting, 276 and the corresponding nationwide surge in COVID-19 cases. Our data confirm that the surge

also impacted the pediatric population, correlating with a large increase in the number of SARS-CoV-2-exposed children.

279 It is well appreciated that underrepresented racial and ethnic groups are disproportionately affected by the COVID-19 pandemic.³⁶ We found that Hispanic children were 280 281 more likely to have SARS-CoV-2 antibodies compared to white children in all waves. Similarly, 282 black children were more likely to have antibodies than white children in Wave 3 and Wave 5. The increase in SARS-CoV-2 antibodies in Hispanic and black children corresponded to an 283 284 increase in antibody level in Hispanic and black adults during the same timeframe.(REF-285 Kennedy preprint) Higher antibody prevalence in Hispanic and black children may reflect 286 multiple socioeconomic factors, including income inequality, economic stability, work circumstances, and housing.³⁷ Hispanic and black parents may be less likely to hold jobs that 287 288 allow them to work remotely, which increases their potential exposure to SARS-CoV-2 in the 289 workplace and limits their ability to utilize remote learning or in home childcare to decrease their children's SARS-CoV-2 exposure.^{38,39} Residing with parents with a higher risk of workplace 290 291 SARS-CoV-2 exposure combined with increased school/daycare attendance could drive 292 infection rates in minority children. Our results underscore that the pandemic exacerbated 293 existing racial and ethnic disparities.

294 Our data also highlight the importance of vaccinating children against SARS-CoV-2. General vaccinations in Arkansas began in January 2021 for those over 18 years and, and were 295 expanded to 16 years and older on March 30, 2021.⁴⁰ The CDC's Advisory Committee on 296 297 Immunization Practices recommended the Pfizer-BioNTech vaccine for 12-15 year-olds on May 10, 2021.⁴⁰ Wave 5 samples were collected in April 2021, after the expansion of vaccinations to 298 299 those 16 years and up but prior to inclusion of 12-15 year-olds. Only 8 of 145 total 16-18 year-300 olds in reported being vaccinated during Wave 5 and no subjects reported full vaccination at 301 least two weeks prior to sample collection. Thus, our data reflect the pediatric seroprevalence 302 rate in Arkansas prior to widespread vaccination efforts in children and adolescents. As 303 authorization to vaccinate children younger than 12 years will not occur until late 2021, our 304 findings indicate that most children in Arkansas remain susceptible to SARS-CoV-2 infection

entering the 2021–2022 school year. Importantly, we found that the seroprevalence rate in
younger children was lower than for older children and adolescents, which strongly emphasizes
the ongoing risk of infection for a vulnerable part of the population that cannot yet be
vaccinated. This is a critical consideration for policy makers as more infectious variants emerge
that exhibit increased infection and likelihood of causing sever disease in younger portions of
the population.

311 Limitations

312 Remnant serum samples may not provide an accurate representation of the Arkansas population. The strengths and limitations of convenience samples are described elsewhere.⁴¹ 313 314 As our study samples were collected from health clinics, our sampling method may favor 315 subjects who were more ill or more willing to seek health care. It is possible that our 316 seroprevalence rates are overestimated due to potential cross reactivity between SARS-CoV-2 antigens and seasonal coronaviruses.⁴² Some uninfected individuals, particularly children and 317 adolescents, have antibodies that react with the SARS-CoV-2 Spike protein.⁴² Further, we 318 319 measured a combination of IgM and IgG antibody isotypes, as opposed to testing solely for 320 IgG.⁴³ Although studies indicate that IgG and IgM responses to SARS-CoV-2 can develop 321 simultaneously, some individuals develop detectable IgM and IgG antibodies at different 322 times.^{44,45} Consequently, we may identify individuals that developed IgM and/or IgG, whereas 323 other assays may only identify specimens with IgG. Moreover, IgM can be more non-specific than IgG.⁴⁶ Together, these limitations may cause an overestimation of antibody reactivity. 324 325 However, inclusion of multiple SARS-CoV-2 antigens and the BSA control limit the number of 326 non-specific reactions detected in our assay.

327

328 CONCLUSIONS

Analysis of remnant samples collected from children and adolescents in Arkansas
 demonstrate a steady increase in SARS-CoV-2 infection during the first 8 months of the

331 pandemic, followed by a more rapid increase to 25% by the end of April 2021. This finding is 332 notable, as it is more than twice the number of confirmed SARS-CoV-2 diagnoses in the state 333 on the final collection date. No obvious comorbidities were identified for seropositivity in 334 children. Racial and ethnic disparities exist, with Hispanic and black children being at increased 335 risk for SARS-CoV-2 infection compared to white children. We conclude that SARS-CoV-2 336 infections in children are more common than previously recognized. With the emergence of 337 SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or 338 asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these 339 results highlight the importance of including children in SARS-CoV-2 public health, clinical care, 340 and research strategies. Until vaccines are approved for those under 12 years, it is important 341 that protective measures are enacted, particularly in settings where children are grouped 342 together, to limit the risk of infection, super-spreader events, severe disease, long-term 343 sequelae, and death. This is especially true in states like Arkansas with low vaccination rates. 344 which is currently experiencing a new surge in infections and hospitalizations in younger age-345 groups caused by more infectious SARS-CoV-2 variants.

346

347 ACKNOWLEDGMENTS

348 This research was supported by funds from the state of Arkansas through the

349 Coronavirus Aid, Relief, and Economic Security (CARES) Act, the UAMS Time-Sensitive

350 COVID-10 Research Award Program, the UAMS Translational Research Institute

351 (UL1TR000039, TL1TR003109, and UL1TR003107), and the Center for Microbial Pathogenesis

and Host Inflammatory Response (P20 GM103625).

354 FIGURE LEGENDS

Figure 1 Timeline of Arkansas COVID-19 milestones and sample collection waves. The schematic shows the timeline for relevant study-related events. The sample collection periods are indicated by blue boxes. The seroprevalence rate for each wave is indicated as the percent (95% CI).

359	Author Contributions: Drs. Boehme, Forrest, and Kennedy had full access to all of the data in
360	the study and take responsibility for the integrity of the data and the accuracy of the analysis.
361	
362	Study concept and design: Boehme, Forrest, Kennedy, Snowden
363	
364	Acquisition, analysis or interpretation of the data: Boehme, Boyanton, Caid, Forrest, Owens,
365	Kennedy, Kirkpatrick, Kothari, Kouassi, Mann, Modi, Paredes, Putt, Zohoori
366	
367	Draft of the manuscript: Boehme, Forrest, Kennedy, Owens
368	
369	Critical revision of the manuscript for important intellectual content: Boehme, Forrest, James,
370	Kennedy, Owens, Snowden
371	
372	Statistical analysis: Jin, Du
373	
374	Obtained funding: Boehme, Forrest, James, Kennedy
375	
376	Administrative, technical, or material support: Boehme, Boyanton, Forrest, James, Kennedy,
377	Snowden

Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in wuhan,

378 **REFERENCES**

1.

379

china: The mystery and the miracle. J Med Virol. 2020;92(4):401-402. 380 2. 381 Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in 382 china, 2019. N Engl J Med. 2020;382(8):727-733. 383 3. World health organization. WHO Coronavirus Dashboard https://covid19.who.int/. 384 Team CC-R, Jorden MA, Rudman SL, et al. Evidence for limited early spread of covid-19 4. 385 within the united states, january-february 2020. MMWR Morb Mortal Wkly Rep. 386 2020;69(22):680-684. 387 5. United states centers for disease control and prevention. COVID Data Tracker 388 https://covid.cdc.gov/covid-data-tracker/#datatracker-home. 389 6. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the 390 united states. N Engl J Med. 2020;382(10):929-936. 391 7. Jean-Baptiste CO, Herring RP, Beeson WL, Dos Santos H, Banta JE, Stressful life 392 events and social capital during the early phase of covid-19 in the u.S. Soc Sci Humanit 393 Open. 2020;2(1):100057. 394 8. Bayham J, Fenichel EP. Impact of school closures for covid-19 on the us health-care 395 workforce and net mortality: A modelling study. Lancet Public Health. 2020;5(5):e271-396 e278. 397 9. Hobbs CV, Drobeniuc J, Kittle T, et al. Estimated sars-cov-2 seroprevalence among 398 persons aged <18 years - mississippi, may-september 2020. MMWR Morb Mortal Wkly 399 Rep. 2021;70(9):312-315. 400 Bajema KL, Wiegand RE, Cuffe K, et al. Estimated sars-cov-2 seroprevalence in the us 10. 401 as of september 2020. JAMA Intern Med. 2021;181(4):450-460. 402 11. Dong Y, Mo X, Hu Y, et al. Epidemiology of covid-19 among children in china. *Pediatrics*. 403 2020;145(6). Oran DP, Topol EJ. Prevalence of asymptomatic sars-cov-2 infection. Ann Intern Med. 404 12. 405 2021;174(2):286-287. 406 Oran DP, Topol EJ. The proportion of sars-cov-2 infections that are asymptomatic : A 13. 407 systematic review. Ann Intern Med. 2021;174(5):655-662. 408 14. United states centers for disease control and prevention. CDC Diagnostic Tests for 409 COVID-19 https://www.cdc.gov/coronavirus/2019-ncov/lab/testing.html. 410 Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to sars-cov-2 in 10 sites 15. 411 in the united states, march 23-may 12, 2020. JAMA Intern Med. 2020. 412 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic 413 data capture (redcap)--a metadata-driven methodology and workflow process for 414 providing translational research informatics support. J Biomed Inform. 2009;42(2):377-415 381. 416 Harris PA, Taylor R, Minor BL, et al. The redcap consortium: Building an international 17. 417 community of software platform partners. J Biomed Inform. 2019;95:103208. 418 18. Stadlbauer D, Amanat F, Chromikova V, et al. Sars-cov-2 seroconversion in humans: A 419 detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc 420 Microbiol. 2020;57(1):e100. 421 Mark J, Li X, Cyr T, Fournier S, Jaentschke B, Hefford MA. Sars coronavirus: Unusual 19. 422 lability of the nucleocapsid protein. Biochem Biophys Res Commun. 2008;377(2):429-423 433. 424 20. Leclercg I, Batejat C, Burguiere AM, Manuguerra JC. Heat inactivation of the middle east 425 respiratory syndrome coronavirus. Influenza Other Respir Viruses. 2014;8(5):585-586. 426 21. Yunoki M, Urayama T, Yamamoto I, Abe S, Ikuta K. Heat sensitivity of a sars-associated 427 coronavirus introduced into plasma products. Vox Sang. 2004;87(4):302-303.

428	22	Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW, Stability and
429		inactivation of sars coronavirus. <i>Med Microbiol Immunol.</i> 2005;194(1-2):1-6.
430	23.	Kariwa H, Fujii N, Takashima I. Inactivation of sars coronavirus by means of povidone-
431		iodine, physical conditions and chemical reagents. <i>Dermatology</i> . 2006;212 Suppl 1:119-
432		123.
433	24.	Duan SM, Zhao XS, Wen RF, et al. Stability of sars coronavirus in human specimens
434		and environment and its sensitivity to heating and uv irradiation. <i>Biomed Environ Sci.</i>
435		2003;16(3):246-255.
436	25.	Chang L, Yan Y, Wang L. Coronavirus disease 2019: Coronaviruses and blood safety.
437		Transfus Med Rev. 2020;34(2):75-80.
438	26.	Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect sars-cov-2
439		seroconversion in humans. Nat Med. 2020;26(7):1033-1036.
440	27.	United states census bureau. Quickfacts: Arkansas 2021;
441		https://www.census.gov/quickfacts/AR. Accessed May 14, 2021.
442	28.	Zou G. A modified poisson regression approach to prospective studies with binary data.
443		Am J Epidemiol. 2004;159(7):702-706.
444	29.	Havers FP, Whitaker M, Self JL, et al. Hospitalization of adolescents aged 12-17 years
445		with laboratory-confirmed covid-19 - covid-net, 14 states, march 1, 2020-april 24, 2021.
446		MMWR Morb Mortal Wkly Rep. 2021;70(23):851-857.
447	30.	Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. Sars-cov-2 b.1.617.2 (delta)
448		variant covid-19 outbreak associated with a gymnastics facility - oklahoma, april-may
449		2021. MMWR Morb Mortal Wkly Rep. 2021;70(28):1004-1007.
450	31.	Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in
451		children in new york state. <i>N Engl J Med.</i> 2020;383(4):347-358.
452	32.	Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in u.S.
453	<u> </u>	Children and adolescents. N Engl J Med. 2020;383(4):334-346.
454	33.	Ouldali N, Yang DD, Madhi F, et al. Factors associated with severe sars-cov-2 infection.
455	0.4	Pediatrics. 2021;147(3).
456	34.	James A, Eagle L, Phillips C, et al. High covid-19 attack rate among attendees at events
457		al a church - alkansas, march 2020. MINIWR Morb Mortal Wkly Rep. 2020;69(20):632-
400	25	000. Arkansas department of health COVID 10 Tracker
409	35.	https://ovporioneco.aregic.com/ovporioneco/622006d0792b4544bd5112o214f6269o/
400		<u>Accessed July 20, 2021</u>
462	36	Khunti K Platt I Routen & Abbasi K Covid-19 and ethnic minorities: An urgent agenda
463	50.	for overdue action BML 2020:360 m 2503
464	37	United states bureau of labor statistics. Labor force characteristics by race and ethnicity
465	07.	2019 https://www.bls.gov/opub/reports/race-and-ethnicity/2019/home.htm. Accessed
466		July 22, 2021.
467	38	Yancy CW. Covid-19 and african americans. JAMA: 2020:323(19):1891-1892
468	39.	Ambrose AJH. Inequities during covid-19. <i>Pediatrics</i> . 2020;146(2).
469	40.	Arkansas pharmacists association. COVID Vaccine 2021: https://www.arrx.org/covid-
470	-	vaccine, Accessed May 30, 2021.
471	41.	Shook-Sa BE, Boyce RM, Aiello AE, Estimation without representation: Early severe
472		acute respiratory syndrome coronavirus 2 seroprevalence studies and the path forward.
473		J Infect Dis. 2020;222(7):1086-1089.
474	42.	Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to
475		sars-cov-2 in humans. Science. 2020;370(6522):1339-1343.
476	43.	Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven
477		serology assays reveals a sars-cov-2 non-responding seronegative subpopulation.
478		EClinicalMedicine. 2020;29:100651.

- 479 44. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to sars-cov-2 in patients with covid-19. *Nat Med.* 2020;26(6):845-848.
- 481 45. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic sars-cov-2 infections. *Nat Med.* 2020;26(8):1200-1204.
- 483 46. Shah J, Liu S, Potula HH, et al. Igg and igm antibody formation to spike and
- 484 nucleocapsid proteins in covid-19 characterized by multiplex immunoblot assays. *BMC*485 *Infect Dis.* 2021;21(1):325.
- 486

Table 1. Demographics of sampled populations in Arkansas during 5 periods of SARS-CoV-2 antibody testing from April 2, 488 2020 to April 28, 2021. 489

	Number (%) ^a					
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
Age category						
1-4 years	56 (17.7)	33 (11)	81 (13.6)	83 (13.9)	75 (12.8)	328 (13.7)
5-9 years	61 (19.3)	75 (25)	112 (18.9)	116 (19.5)	142 (24.2)	506 (21.1)
10-14 years	90 (28.5)	98 (32.7)	205 (34.5)	214 (36.0)	188 (32)	795 (33.2)
15-18 years	109 (34.5)	94 (31.3)	196 (33)	182 (30.6)	183 (31.1)	764 (31.9)
Sex						
Female	161 (50.9)	155 (51.7)	324 (54.5)	338 (56.8)	333 (56.5)	1311 (54.8)
Male	155 (49.1)	145 (48.3)	270 (45.5)	257 (43.2)	255 (43.2)	1082 (45.2)
Race/Ethnicity						
White	178 (56.5)	154 (52.2)	327 (57.2)	312 (54.5)	318 (57.2)	1289 (55.8)
Black	91 (28.9)	53 (18.0)	117 (20.5)	150 (26.2)	109 (19.6)	520 (22.5)
Hispanic	28 (8.9)	64 (21.7)	95 (16.6)	77 (13.4)	87 (15.7)	351 (15.2)
Other	18 (5.7)	24 (8.1)	33 (5.8)	34 (5.9)	42 (7.6)	151 (6.5)
Metropolitan status ^b						
Urban	Not Reported	251 (83.7)	458 (77.1)	424 (71.3)	431 (73.3)	1564 (75.3)
Rural	Not Reported	49 (16.3)	136 (22.9)	171 (28.7)	157 (26.7)	513 (24.7)

^aPercentages calculated from non-missing values for all periods. Missing values in Wave 1 included race/ethnicity (n=1) and metropolitan status (n=316). Missing values in Wave 2 included race/ethnicity (n=5). Missing values in Wave 3 included race/ethnicity (n=22). Missing values in Wave 4 included age category (n=5), sex (n=5), race/ethnicity (n=27), and metropolitan status (n=5). Missing values in Wave 5 included age category (n=4), sex (n=2), race/ethnicity (n=34), and metropolitan status (n=2).

494

medRxiv preprint doi: https://doi.org/10.1101/2021.08.04.21261592; this version posted August 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

495	Table 2. Age-specific, sex-specific, race/ethnicity-specific seroprevalence estimates in Arkansas during 5 periods of SARS-
496	CoV-2 antibody testing from April 2, 2020 to April 28, 2021.

	Persons reactive, % (9	95% CI) (No.)			
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021
Age category					
1-4 years	10.7 (2.4-19.1) (6)	15.2 (2.2-28.1) (5)	19.8 (10.9-28.6) (16)	7.2 (1.54-12.9) (6)	16.0 (7.5-24.5) (12)
5-9 years	4.9 (0.0-10.5) (3)	8.0 (1.7, 14.3) (6)	18.8 (11.4-26.1) (21)	12.9 (6.7-19.1) (15)	19.0 (12.5,-25.5) (27)
10-14 years	8.9 (2.9-14.9) (8)	11.2 (4.9-17.6) (11)	14.2 (9.3-19.0) (29)	14.0 (9.3-18.7) (30)	30.9 (24.2-37.5) (58)
15-18 years	7.3 (1.4-12.3) (8)	7.4 (2.0-12.9) (7)	15.3 (10.2-20.4) (30)	14.8 (9.6-20.0) (27)	29.5 (22.8-36.2) (54)
Sex					
Female	8.7 (4.3-13.1) (14)	9.0 (4.5-13.6) (14)	17.3 (13.1-21.4) (56)	13.6 (9.9-17.3) (46)	27.0 (22.2-31.8) (90)
Male	7.1 (3.0-11.2) (11)	10.3 (5.3-15.4) (15)	14.8 (10.6-19.1) (40)	12.5 (8.4-16.5) (32)	23.9 (18.7-29.2) (61)
Race/Ethnicity					
White	9.0 (4.7-13.2) (16)	9.7 (5.0-14.5) (15)	10.7 (7.3-14.1) (35)	11.5 (8.0-15.1) (36)	17.9 (13.7-22.2) (57)
Black	5.5 (0.7-10.3) (5)	3.8 (0.0-9.1) (2)	17.1 (10.2-24.0) (20)	15.3 (9.5-21.2) (23)	28.4 (19.8-37.0) (31)
Hispanic	10.7 (0.0-22.9) (3)	14.1 (5.3-22.8) (9)	29.5 (20.1-38.8) (28)	20.8 (11.5-30.0) (16)	43.7 (33.0-54.3) (38)
Other	5.6 (0.0 -7.3) (1)	12.5 (0.0-26.8) (3)	27.3 (11.2-43.4) (9)	2.9 (0.0-8.9) (1)	35.7 (20.6-50.8) (15)
Total	7.9 (4.9-10.9) (25)	9.7 (6.3-13.0) (29)	16.2 (13.2-19.1) (96)	13.2 (10.5-15.9) (79)	25.8 (22.2-29.3) (152)
Age- and sex-Standardized seroprevalence rate ^a , % (95% CI)	8.6 (5.1-12.1)	9.8 (6.1-13.6)	16.9 (13.3-20.6)	12.5 (9.6-15.5)	24.2 (20.1-28.2)

497 498

^aStandardized positivity rates were calculated based on the 2019 U.S. Census Bureau Arkansas state population estimates (age ≤ 18).²⁷

	Adjusted RR (95% CI)	1			
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 592)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021
Age category					
1-4 years	1.66 (0.55-5.02)	1.89 (0.67-5.35)	1.41 (0.82-2.43)	0.62 (0.26-1.45)	0.50 (0.28-0.90)
5-9 years	0.65 (0.18-2.41)	0.97 (0.34-2.74)	1.46 (0.88-2.41)	0.95 (0.52-1.75)	0.72 (0.47-1.09)
10-14 years	1.23 (0.46-3.29)	1.36 (0.54-3.43)	0.95 (0.59-1.53)	1.04 (0.64-1.68)	0.90 (0.66-1.24
15-18 years	Ref	Ref	Ref	Ref	Ref
Sex					
Female	1.37 (0.61-3.06)	0.88 (0.44-1.75)	1.04 (0.71-1.52)	1.12 (0.73-1.73)	1.06 (0.80-1.40)
Male	Ref	Ref	Ref	Ref	Ref
Race/Ethnicity					
Black	0.59 (0.23-1.54)	0.41 (0.09-1.83)	1.71 (1.03-2.84)	1.31 (0.80-2.14)	1.59 (1.08-2.34)
Hispanic	1.21 (0.37-3.93)	1.53 (0.70-3.37)	2.82 (1.81-4.38)	1.76 (1.03-3.00)	2.37 (1.69-3.33)
Other	0.54 (0.07-4.36)	1.25 (0.41-3.81)	2.59 (1.36-4.92)	0.25 (0.04-1.80)	2.14 (1.35-3.40)
White	Ref	Ref	Ref ^a	Ref	Ref ^a

499 Table 3. Age- and sex-adjusted association with SARS-CoV-2 antibody positivity by time period.

500 501

^aIndicates P value < 0.0001 for race/ethnicity in the statistical model.

502 Supplemental table 1. Co-morbidities of sampled populations in Arkansas during 5 periods of SARS-CoV-2 antibody testing 503 from April 2, 2020 to April 29, 2021.

	Number (%) ^a					
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
Respiratory viral panel within 6 months	Not Reported	34 (11.3)	35 (5.9)	25 (4.2)	Not reported	94 (6.3)
Asthma	12 (3.8)	31 (10.3)	68 (11.5)	62 (10.4)	66 (11.2)	239 (10.0)
Hypertension	16 (5.1)	16 (5.3)	25 (4.2)	34 (5.7)	20 (3.4)	111 (4.6)
Obesity	14 (4.4)	46 (15.3)	83 (14.0)	109 (18.3)	85 (14.4)	337 (14.1)
Diabetes	10 (3.2)	15 (5.0)	30 (5.1)	27 (4.5)	31 (5.3)	113 (4.7)
Autoimmune disease	Not Reported	7 (2.3)	14 (2.4)	19 (3.2)	23 (3.9)	63 (3.0)

^a Percentages calculated from non-missing values for all periods. Missing values in Wave 1 included respiratory virus panel performed within 6 months (n = 316) and autoimmune disease (n = 316), Missing values in Wave 4 included respiratory virus panel performed within 6 months (n = 5), asthma (n = 5), hypertension (n = 5), obesity (n = 5), diabetes (n = 5), and autoimmune disease (n = 5). Missing values in Wave 5 included Respiratory virus panel within 6 months (n = 59).

Supplemental table 2. Marginal association between SARS-CoV-2 antibody positivity and demographic characteristics by 510 time period.

511 512

		Maya 1			Maya 2		1	Maya 2			Waya 4			Move F	
		(n = 316)			(n = 300)			(n = 594)			(n = 600)			(n = 590)	
Characteristic ^a	No., (%)	RR (95% CI)	P	No., (%)	RR (95%CI)	Pb	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	P
Total	25 (7.9)			29 (9.7)			96 (16.2)			79 (13.2)			152 (25.8)		
Age category 1-4 5-9 10-14 15-18	6 (10.7) 3 (4.9) 8 (8.9) 8 (7.3)	1.46 (0.53-4.00) 0.67 (0.18-2.43) 1.21 (0.47-3.10) Ref	0.690	5 (15.2) 6 (8.0) 11 (11.2) 7 (7.5)	2.03 (0.69-5.97) 1.07 (0.38-3.06) 1.51 (0.61-3.72) Ref	0.539	16 (19.8) 21 (18.8) 29 (14.2) 30 (15.3)	1.29 (0.75-2.23) 1.23 (0.74-2.03) 0.92 (0.58-1.48) Ref	0.560	6 (7.2) 15 (12.9) 30 (14.0) 27 (14.8)	0.49 (0.21-1.14) 0.87 (0.48-1.57) 0.95 (0.58-1.53) Ref	0.410	12 (16.0) 27 (19.0) 58 (30.9) 54 (29.5)	0.54 (0.31-0.95) 0.64 (0.43-0.97) 1.05 (0.77-1.43) Ref	0.0
Sex Female Male	14 (8.7) 11 (7.1)	1.23 (0.57, 2.62) Ref	0.600	14 (9.0) 15 (10.3)	0.87 (0.44, 1.74) Ref	0.701	56 (17.3) 40 (14.8)	1.17 (0.80, 1.69) Ref	0.417	46 (13.6) 32 (12.5)	1.09 (0.72, 1.67) Ref	0.679	90 (27.0) 61 (23.9)	1.13 (0.85, 1.50) Ref	0.39 It is:
Race/ethnicity Black Hispanic Others White	5 (5.5) 3 (10.7) 1 (5.6) 16 (9.0)	0.61 (0.23-1.62) 1.19 (0.37-3.83) 0.62 (0.09-4.39) Ref	0.706	2 (3.8) 9 (14.1) 3 (12.5) 15 (9.7)	0.39 (0.09-1.64) 1.44 (0.67-3.13) 1.28 (0.40-4.10) Ref	0.352	20 (17.1) 28 (29.5) 9 (27.3) 35 (10.7)	1.60 (0.96-2.65) 2.75 (1.77-4.28) 2.55 (1.34-4.83) Ref	<0.0001	23 (15.3) 16 (20.8) 1 (2.9) 36 (11.5)	1.33 (0.82-2.16) 1.80 (1.06-3.07) 0.25 (0.04-1.80) Ref	0.060	31 (28.4) 38 (43.7) 15 (35.7) 57 (17.9)	1.59 (1.09-2.32) 2.44 (1.74-3.41) 1.99 (1.25-3.18) Ref	∯ade ava
Metropolitan status Urban Rural	NA	NA	NA	28 (11.2) 1 (2.0)	5.47 (0.76-39.24) Ref	0.091	76 (16.6) 20 (14.7)	1.13 (0.72-1.78) Ref	0.602	55 (13.0) 23 (13.5)	0.96 (0.61-1.52) Ref	0.876	101 (23.4) 50 (31.9)	0.74 (0.55-0.98) Ref	allable

^a Missing values from Table 1 were not included in the analysis.

^bP-value indicates whether the positivity differs between the category of a respective variable.

517 Supplemental table 3. Marginal association between SARS-CoV-2 antibody positivity and comorbidities by time period.

		Wave 1 (n = 316)			Wave 2 (n = 300)			Wave 3 (n = 594)			Wave 4 (n = 600)			Wave 5 (n = 590)	
Characteristic ^a	No., (%)	RR (95% CI)	P	No., (%)	RR (95%CI)	P	No., (%)	RR (95% CI)	P ^b	No., (%)	RR (95% CI)	₽⋼	No., (%)	RR (95% CI)	P
Total	25 (7.9)			29 (9.7)			96 (16.2)			79 (13.2)			152 (25.8)		5
Respiratory virus panel within 6 months Yes	NA	NA	NA	6 (17.7)	2.04 (0.89-4.65)	0.090	7 (20.0)	1.26 (0.63-2.50)	0.517	0	NA	NA	NA	NA	NA
No				23 (8.7)	Ref		89 (15.9)	Ref		78 (13.7)					7
Asthma			0.003			0.192			0.099			0.231			0.76
Yes No	4 (33.3) 21 (6.9)	4.83 (1.96-11.87) Ref		5 (16.1) 24 (8.9)	1.81 (0.74-4.40) Ref		6 (8.8) 90 (17.1)	0.52 (0.23-1.13) Ref		5 (8.1) 73 (13.7)	0.59 (0.25-1.40) Ref		16 (24.2) 136 (26.0)	0.93 (0.60-1.47) Ref	3
Hypertension						0.643			0.258			0.775			0.30
Yes No	0 25 (8.3)	NA	NA	1 (6.3) 28 (9.9)	0.63 (0.09-4.37) Ref		6 (24.0) 90 (15.8)	1.52 (0.74-3.13) Ref		5 (14.7) 73 (13.0)	1.13 (0.49-2.61) Ref		7 (35.0) 145 (25.4)	1.38 (0.74-2.54) Ref	Ξ
Obesity						0.763			0.607			0.589			<u>6</u> .61
Yes No	1 (7.1) 24 (8.0)	0.90 (0.13-6.18) Ref	0.914	5 (10.9) 24 (9.5)	1.15 (0.46-2.86) Ref		15 (18.1) 81 (15.9)	1.14 (0.69-1.88) Ref		16 (14.7) 62 (12.8)	1.15 (0.69-1.91) Ref		20 (23.5) 132 (26.1)	0.90 (0.60-1.36) Ref	mac
Diabetes			0.007						0.938			0.391			A
Yes No	3 (30.0) 22 (7.2)	4.17 (1.49-11.67) Ref		0 29 (10.2)	NA	NA	5 (16.7) 91 (16.1)	1.03 (0.45-2.35) Ref		2 (7.4) 76 (13.4)	0.55 (0.14-2.14) Ref		12 (38.7) 140 (25.0)	1.55 (0.97-2.46) Ref	ava
Autoimmune disease Yes No	NA	NA	NA	1 (14.3) 28 (9.6)	1.49 (0.24-9.49) Ref	0.670	2 (14.3) 94 (16.2)	0.88 (0.24-3.22) Ref	0.849	2 (10.5) 76 (13.2)	0.80 (0.21-3.01) Ref	0.739	7 (30.4) 145 (25.6)	1.19 (0.63-2.24) Ref	allable



^a Missing values from Table 1 were not included in the analysis.

^bP-value indicates whether the positivity differs between the category of a respective variable.

523 Supplemental table 4. PCR test history and results from sampled populations in Arkansas during 5 periods of SARS-CoV-2 524 antibody testing from April 2, 2020 to April 28, 2021.

	Number (%) ^a					
Characteristic	Wave 1 (n = 316)	Wave 2 (n = 300)	Wave 3 (n = 594)	Wave 4 (n = 600)	Wave 5 (n = 590)	Overall (N = 2400)
Collection dates	April 2 – May 6, 2020	June 6 – August 10, 2020	September 8 – October 17, 2020	November 7 – December 17, 2020	April 5 – April 28, 2021	April 2, 2020 – April 28, 2021
SARS-CoV-2 RT-PCR test administered						
Yes	64 (20.3)	82 (27.3)	160 (26.9)	173 (29.1)	235 (39.8)	714 (29.8)
No	252 (79.7)	218 (72.7)	434 (73.1)	422 (70.9)	355 (60.2)	1681 (70.2)
SARS-CoV-2 RT-PCR test result						
Positive	0 (0.0)	1 (1.2)	6 (3.8)	11 (6.4)	20 (8.6)	38 (5.3)
Negative	64 (100)	81 (98.8)	154 (96.2)	162 (93.6)	214 (91.5)	675 (94.7)

^a Percentages calculated from non-missing values for all periods. Missing values in Wave 1 included SARS-CoV-2 RT-PCR test result (n = 252). Missing values in Wave 2 included SARS-CoV-2 RT-PCR test result (n = 434). Missing values in Wave 4 included SARS-CoV-2 RT-PCR test result (n = 434). Missing values in Wave 4 included SARS-CoV-2 RT-PCR test administered (n = 5) and SARS-CoV-2 RT-PCR test result (n = 427). Missing values in Wave 5 included SARS-CoV-2 PCR test result (n = 356)

Supplemental table 5. Marginal association between SARS-CoV-2 antibody positivity and SARS-CoV-2 PCR testing by time 531 532 533 period.

															-
	Wave 1 (n = 316)			Wave 2 (n = 300)			Wave 3 (n = 594)			Wave 4 (n = 600)			Wave 5 (n = 590)		
Characteristic ^a	No., (%)	RR (95% CI)	P	No., (%)	RR (95%CI)	P	No., (%)	RR (95% CI)	P	No., (%)	RR (95% CI)	P	No., (%)	RR (95% CI)	P
Total	25 (7.9)			29 (9.7)			96 (16.2)			79 (13.2)			152 (25.8)		
COVID-19 test administered			0.585			0.178			0.589			0.655			0.49
Yes	4 (6.3)	0.75 (0.27-2.11)		11 (13.4)	1.62 (0.80-3.29)		28 (17.5)	1.12 (0.75-1.67)		21 (12.1)	0.90 (0.56-1.44)		57 (24.3)	0.91 (0.68-1.20)	1 5
No	21 (8.3)	Ref		18 (8.3)	Ref		68 (15.7)	Ref		57 (13.5)	Ref		95 (26.8)	Ref	
COVID-19 PCR result						< 0.0001			< 0.0001			< 0.0001			< 0.00
Positive	0	NA	NA	1 (100)	8.10 (4.53-14.47)		4 (66.7)	4.28 (2.18-8.40)		8 (72.7)	9.06 (4.80-17.10)		17 (85.0)	4.55 (3.25-6.35)	1 3
Negative	4 (6.3)			10 (12.4)	Ref		24 (15.6)	Ref		13 (8.0)	Ref		40 (18.7)	Ref	1 2

534 536

^a Missing values from Table 1 were not included in the analysis.

^bP-value indicates whether the positivity differs between the category of a respective variable.

